Company Filing History:
Years Active: 2015-2018
Title: Innovations by Inventor Nicolas Boute
Introduction
Nicolas Boute is a notable inventor based in Cernex, France. He has made significant contributions to the field of biotechnology, particularly in the development of methods for generating and screening antibody libraries. With a total of four patents to his name, Boute's work is focused on advancing cancer treatment through innovative approaches.
Latest Patents
One of Boute's latest patents is a method for generating and screening an antibody library. This invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA derived from a cell capable of producing an antibody. More specifically, it involves the generation of a monoclonal antibody library and the use of this library for screening monoclonal antibodies, preferably human antibodies, for treating cancer. Another significant patent is for an antigen binding protein and its use as an addressing product for cancer treatment. This invention pertains to a monoclonal antibody capable of specifically binding to the protein Axl, along with the amino and nucleic acid sequences coding for this protein. The invention also includes the use of the antigen binding protein in conjunction with other anti-cancer compounds, such as toxins, radio-elements, or drugs, for the treatment of certain cancers.
Career Highlights
Throughout his career, Nicolas Boute has worked with prominent companies in the pharmaceutical industry, including Pierre Fabre Medicament. His experience in these organizations has contributed to his expertise in the field of antibody development and cancer treatment.
Collaborations
Boute has collaborated with several professionals in his field, including Charlotte Beau-Larvor and Liliane Goetsch. These collaborations have likely enhanced his research and development efforts in biotechnology.
Conclusion
Nicolas Boute's innovative work in generating antibody libraries and developing targeted cancer treatments showcases his significant contributions to biotechnology. His patents reflect a commitment to advancing medical science and improving patient outcomes.